Drug Target Review2025-05-02T08:30:04
A new study by Scripps Research reveals that apremilast, an FDA-approved anti-inflammatory drug, may help reduce both alcohol consumption and pain sensitivity, offering a potential dual therapy for alcohol use disorder.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-03T12:09:00Z
2024-01-10T08:56:17
Sponsored by Leica Microsystems
2025-05-28T14:00:00
Sponsored by Eurofins DiscoverX
2026-10-07T14:00:00
Sponsored by WuXi AppTec
2026-05-22T07:38:00
Contributor Dr Helen Bright, Drug Target Review
2026-09-22T07:00:00
Contributor Luca Lotta, Drug Target Review
2024-01-09T10:09:08
Sponsored by Sartorius iQue®
Site powered by Webvision Cloud